A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19
et al., NCT04537806, NCT04537806, Jul 2022
RCT 28 ventilated patients, showing no significant difference with brexanolone treatment.
Standard of Care (SOC) for COVID-19 in the study country,
the USA, is very poor with very low average efficacy for approved treatments1.
Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
This may explain in part the very high mortality seen in this study.
Results may differ in countries with improved SOC.
|
risk of death, 14.3% higher, RR 1.14, p = 1.00, treatment 8 of 14 (57.1%), control 7 of 14 (50.0%), day 40.
|
|
risk of death, 33.3% higher, RR 1.33, p = 0.71, treatment 8 of 14 (57.1%), control 6 of 14 (42.9%), day 28.
|
|
respiratory failure or death, no change, RR 1.00, p = 1.00, treatment 10 of 14 (71.4%), control 10 of 14 (71.4%), day 28.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Brown et al., 27 Jul 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04537806 (history).
Contact: info@sagerx.com.